Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...

Arcellx (ACLX) and Legend Biotech (LEGN) traded higher on Tuesday after the U.S. FDA issued draft guidance on the use of minimal residual disease and complete response as study endpoints that can ...

The US Food and Drug Administration (FDA) yesterday issued a draft guidance for industry that provides recommendations to ...

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug ...

Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...

An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...

To Jagannath, cure means long periods of disease-free survival as defined by minimal residual disease (MRD) criteria, 10 -5 or 10 -6 cells in bone marrow. Many hematologists agree, including Patel, ...

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for ...

By the time a Florida mom of two finally heard the words "multiple myeloma," she had already spent months being told her ...